This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

William S. Marth Appointed To AMRI's Board Of Directors

ALBANY, N.Y., May 7, 2012 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI), a leading global contract research and manufacturing organization, today announced the appointment of William S. Marth to its Board of Directors. Mr. Marth has extensive experience in leading organizational and operational initiatives at global pharmaceutical companies. As a member of the AMRI board, he will work closely with members of the Board and company leadership to oversee the performance and strategic direction of the company.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

As has been previously announced, Dr. Paul Anderson has informed the Board that he will not stand for re-election at the upcoming annual meeting of shareholders scheduled for June 6, 2012.

Mr. Marth has served as President and Chief Executive Officer - Americas, Teva, since June 2010, after serving as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and as President and Chief Executive Officer of Teva USA from January 2005 to January 2008. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb.

Mr. Marth earned his B.Sc. in Pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University. He is a licensed pharmacist and serves on various boards and committees, including The University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins' Project RESTORE.  Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.

"We are pleased that Mr. Marth has joined AMRI's Board of Directors," said AMRI Chairman, CEO and President Thomas E. D'Ambra, Ph.D. "I am confident Bill's extensive operational experience, pharmaceutical industry knowledge and leadership skills will enable him to provide strategic insight and a unique perspective that will complement the strengths of our existing board members. His addition will benefit AMRI as we continue to manage and develop our global service offerings to address the opportunities and challenges facing the pharmaceutical and biotechnology industries.  I would also like to thank and acknowledge the years of service and contributions of Dr. Paul Anderson to AMRI's board and R&D operations.  Paul has been a friend and trusted advisor.  We wish him well in his retirement."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING , a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information, visit www.amriglobal.com.

SOURCE AMRI

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,526.01 -72.19 -0.41%
S&P 500 2,090.73 -7.31 -0.35%
NASDAQ 5,099.4460 -15.9360 -0.31%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs